Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib

E-ISSN： 1875-533x|19|26|4399-4413

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.19, Iss.26, 2012-09, pp. : 4399-4413

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting JAK2 in the therapy of myeloproliferative neoplasms

By Reddy Mamatha M Deshpande Anagha Sattler Martin

Expert Opinion on Therapeutic Targets, Vol. 16, Iss. 3, 2012-03 ,pp. : 313-324

Informa Healthcare

Access to resources Recommend Favorite

JAK2 inhibitors in the treatment of myeloproliferative neoplasms

By Tibes Raoul Bogenberger James M Geyer Holly L Mesa Ruben A

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 12, 2012-12 ,pp. : 1755-1774

Informa Healthcare

Access to resources Recommend Favorite

New JAK2 inhibitors for myeloproliferative neoplasms

By Quintáás-Cardama Alfonso Verstovsek Srdan

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 7, 2011-07 ,pp. : 961-972

Informa Healthcare

Access to resources Recommend Favorite

Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis

By Vaddi Kris Sarlis Nicholas J Gupta Vikas

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 16, 2012-11 ,pp. : 2397-2407

Informa Healthcare

Access to resources Recommend Favorite

PCM1–JAK2-fusion: a potential treatment target in myelodysplastic–myeloproliferative and other hemato-lymphoid neoplasms

By Hoeller Sylvia Walz Christoph Reiter Andreas Dirnhofer Stephan Tzankov Alexandar

Expert Opinion on Therapeutic Targets, Vol. 15, Iss. 1, 2011-01 ,pp. : 53-62

Informa Healthcare

Access to resources Recommend Favorite